HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spray, T. L. Search for Related Content PubMed PubMed Citation Articles by Spray, T. L.

Ann Thorac Surg 1998;65:S71-S73
© 1998 The Society of Thoracic Surgeons

Use of Aprotinin in Pediatric Organ Transplantation

^a Department of Cardiothoracic Surgery, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

Address reprint requests to Dr Spray, Department of Cardiothoracic Surgery, Children’s Hospital of Philadelphia, 34th St and Civic Center Blvd, Philadelphia, PA 19104

Presented at Risk Assessment of Major Perioperative Issues in Pediatric Cardiac Surgery, Washington, DC, May 7, 1997.

Background. Pediatric thoracic organ transplantation is associated with an increased risk of perioperative bleeding. Many of these patients are undergoing repeat surgical procedures and in general require cardiopulmonary bypass.

Methods. This article reviews the efficacy and safety of the serine protease inhibitor aprotinin in improving hemostasis in pediatric transplantation.

Results. A review of the literature and investigations from Children’s Hospital of Philadelphia suggest that aprotinin is beneficial in pediatric lung transplantation: high-risk patients do as well as low-risk patients. Aprotinin also appears to be of benefit in redo heart transplantations, particularly in patients who have had previous sternotomy or previous transplantation. Repeat use of aprotinin appears to be safe and does reduce blood loss in retransplantation patients. Use in the pump prime and a maintenance dose of aprotinin may be the most effective protocol. At this time, however, it is uncertain whether aprotinin is valuable in primary heart transplantation in low-risk patients.

Conclusions. Current practice at Children’s Hospital of Philadelphia is to use aprotinin in all lung and heart-lung transplantations and in all redo transplantations: lung, heart-lung, and heart. The use of aprotinin in primary heart transplantations is limited to patients who have had previous sternotomies or thoracotomies.

This article has been cited by other articles:

				J. H. Shuhaiber, K. Goldsmith, S. R. Large, and S. Tsui Does perioperative use of aprotinin reduce the rejection rate in heart transplant recipients? Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 849 - 855. [Abstract] [Full Text] [PDF]

				H. A. Hennein Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255. [Abstract] [PDF]